Log In
Print
BCIQ
Print
Print this Print this
 

Retavase, Reteplase (rPA)

  Manage Alerts
Collapse Summary General Information
Company Chiesi Farmaceutici S.p.A.
DescriptionRecombinant plasminogen activator modified to retain activity longer, permitting administration in two single injections
Molecular Target Plasminogen
Mechanism of ActionAnti-thrombotic/thrombolytic
Therapeutic Modality 
Latest Stage of DevelopmentApproved
Standard IndicationMyocardial infarction (MI)
Indication DetailsTreat acute myocardial infarction (AMI); Treat myocardial infarction ((MI) heart attack); Treat myocardial infarction (MI) in combination with ReoPro abciximab platelet antagonist monoclonal antibody
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today